The Health Economics of Genomic Technologies: A Growing Evidence Base on Value.
作者信息
Buchanan James, Goranitis Ilias, Weymann Deirdre
机构信息
Health Economics and Policy Research Unit, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
National Institute for Health Research, Barts Biomedical Research Centre, Queen Mary University of London, London, UK.
出版信息
Appl Health Econ Health Policy. 2025 May;23(3):331-335. doi: 10.1007/s40258-025-00970-z. Epub 2025 Apr 28.
Abstract
摘要
相似文献
1
The Health Economics of Genomic Technologies: A Growing Evidence Base on Value.基因组技术的卫生经济学：基于价值的证据基础不断扩大。
Appl Health Econ Health Policy. 2025 May;23(3):331-335. doi: 10.1007/s40258-025-00970-z. Epub 2025 Apr 28.
2
Health Economics Research on Non-surgical Biomedical HIV Prevention: Identifying Gaps and Proposing a Way Forward.非手术生物医学 HIV 预防的健康经济学研究：识别差距并提出前进方向。
Pharmacoeconomics. 2023 Jul;41(7):787-802. doi: 10.1007/s40273-022-01231-w. Epub 2023 Mar 11.
3
Assessing the Joint Value of Genomic-Based Diagnostic Tests and Gene Therapies.评估基于基因组的诊断测试和基因疗法的联合价值。
J Pers Med. 2019 May 21;9(2):28. doi: 10.3390/jpm9020028.
4
A health services research agenda for cellular, molecular and genomic technologies in cancer care.癌症护理中细胞、分子和基因组技术的卫生服务研究议程。
Public Health Genomics. 2009;12(4):233-44. doi: 10.1159/000203779. Epub 2009 Feb 20.
5
Economics of genomic testing for women with breast cancer.乳腺癌女性基因检测的经济学分析
Am J Manag Care. 2013 Dec;19(12):1024-31.
6
Paving the path for implementation of clinical genomic sequencing globally: Are we ready?为全球临床基因组测序的实施铺平道路：我们准备好了吗？
Health Aff Sch. 2024 Apr 29;2(5):qxae053. doi: 10.1093/haschl/qxae053. eCollection 2024 May.
7
Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group.个性化医学的发展和报销面临的挑战——支付方和制造商的观点，及其对卫生经济学和结果研究的影响：ISPOR 个性化医学特别兴趣小组的报告。
Value Health. 2012 Dec;15(8):1162-71. doi: 10.1016/j.jval.2012.05.006. Epub 2012 Sep 7.
8
Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.用于指导早期乳腺癌女性辅助化疗决策的基因表达谱分析：基于证据的经济分析
Ont Health Technol Assess Ser. 2010;10(23):1-57. Epub 2010 Dec 1.
9
Health care in the developing world: the role of economists and economics.发展中世界的医疗保健：经济学家与经济学的作用。
Soc Sci Med. 1983;17(24):2007-15. doi: 10.1016/0277-9536(83)90141-7.
10
An international consensus panel on the potential value of Digital Surgery.数字手术潜在价值的国际共识小组
BMJ Open. 2024 Sep 5;14(9):e082875. doi: 10.1136/bmjopen-2023-082875.
本文引用的文献
1
The Cost Effectiveness of Genomic Medicine in Cancer Control: A Systematic Literature Review.基因组医学在癌症控制中的成本效益：一项系统文献综述。
Appl Health Econ Health Policy. 2025 May;23(3):359-393. doi: 10.1007/s40258-025-00949-w. Epub 2025 Mar 29.
2
Beyond the Diagnosis: Valuing Genome-Wide Sequencing for Rare Disease Diagnosis Using Contingent Valuation.超越诊断：使用条件价值评估法评估全基因组测序在罕见病诊断中的价值
Appl Health Econ Health Policy. 2025 May;23(3):425-439. doi: 10.1007/s40258-025-00948-x. Epub 2025 Mar 14.
3
Cost-Utility Analysis of Genomic Profiling in Directing Targeted Therapy in Advanced NSCLC in Thailand.泰国晚期非小细胞肺癌基因谱分析指导靶向治疗的成本-效用分析
Appl Health Econ Health Policy. 2025 May;23(3):479-491. doi: 10.1007/s40258-025-00950-3. Epub 2025 Feb 7.
4
Approaches to Incorporation of Preferences into Health Economic Models of Genomic Medicine: A Critical Interpretive Synthesis and Conceptual Framework.将偏好纳入基因组医学健康经济模型的方法：批判性解释性综合与概念框架
Appl Health Econ Health Policy. 2025 May;23(3):337-358. doi: 10.1007/s40258-025-00945-0. Epub 2025 Jan 20.
5
Australian Preferences for Prenatal Screening: A Discrete Choice Experiment Comparing Metropolitan and Rural/Regional Areas.澳大利亚人对产前筛查的偏好：一项比较大都市和农村/地区的离散选择实验。
Appl Health Econ Health Policy. 2025 May;23(3):493-506. doi: 10.1007/s40258-024-00938-5. Epub 2025 Jan 17.
6
Genetic Test Utilization and Cost among Families of Children Evaluated for Genetic Conditions: An Analysis of USA Commercial Claims Data.接受遗传疾病评估儿童家庭的基因检测应用情况及费用：基于美国商业索赔数据的分析
Appl Health Econ Health Policy. 2025 May;23(3):519-530. doi: 10.1007/s40258-024-00942-9. Epub 2025 Jan 8.
7
Exome Sequencing in the Diagnostic Pathway for Suspected Rare Genetic Diseases: Does the Order of Testing Affect its Cost-Effectiveness?疑似罕见遗传病诊断流程中的外显子组测序：检测顺序会影响其成本效益吗？
Appl Health Econ Health Policy. 2025 May;23(3):453-466. doi: 10.1007/s40258-024-00936-7. Epub 2024 Dec 30.
8
Evaluating the Cost-Effectiveness of Etranacogene Dezaparvovec Gene Therapy for Hemophilia B Treatment in the USA.评估依特那考基因德扎帕罗韦克基因疗法在美国治疗B型血友病的成本效益。
Appl Health Econ Health Policy. 2025 May;23(3):467-478. doi: 10.1007/s40258-024-00932-x. Epub 2024 Dec 2.
9
Exploratory Cost-Utility Analysis of a 37-Gene Panel Versus Usual Care to Guide Therapy for Patients with Intermediate-Risk Myeloid Malignancies.37基因检测板与常规治疗对中危髓系恶性肿瘤患者治疗指导的探索性成本效用分析
Appl Health Econ Health Policy. 2025 May;23(3):507-517. doi: 10.1007/s40258-024-00927-8. Epub 2024 Nov 13.
10
Microcosting genomics: Challenges and opportunities.微观成本核算基因组学：挑战与机遇
Genet Med. 2025 Feb;27(2):101310. doi: 10.1016/j.gim.2024.101310. Epub 2024 Nov 7.
Zotero 插件